Navigation Links
Cequent to Provide Details at BIOCOM About Planned Launch of its Clinical Program - 3 p.m., Tuesday, October 27

CAMBRIDGE, Mass., Oct. 13 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that Chief Executive Officer, Peter Parker, will provide details on Cequent's planned launch of its clinical program and highlight strategy and development goals in a company update scheduled for 3 p.m. on Tuesday, October 27, 2009, at the 2009 BIOCOM Investor Conference. The company has initiated a Series B round of financing; it is seeking to raise $15 million to take the company through Phase II clinical trials with its lead drug candidate.

Cequent is using the company's proprietary TransKingdom RNA interference (tkRNAi) technology to develop RNAi-based therapeutics - a new class of drugs designed to work by effectively deactivating the specific gene or genes implicated in the progression of a disease. The company has made considerable progress with its programs targeting polyposis and inflammatory bowel disease (IBD), demonstrating through in vivo testing and studies with non-human primates that its tkRNAi technology can silence target genes successfully. It expects to file its first IND (investigational new drug) application with the U.S. Food and Drug Administration for an orally administered tkRNAi drug targeting the primary oncogene in FAP (familial adenomatous polyposis) before the end of the quarter. FAP is a rare inherited gastrointestinal disease that causes hundreds to thousands of precancerous polyps to form in the colon, leading to colon cancer.

Cequent completed a $15 million Series A financing in June of 2007. Investors included Ampersand Ventures, Pappas Ventures, Yasuda, and the Novartis Option Fund.

2009 BIOCOM Investor Conference

The fourth annual BIOCOM Investor Conference takes place October 26 - 27, 2009, at the Hyatt Regency La Jolla, California. For more information, visit

About Cequent Pharmaceuticals, Inc. (

An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human disorders - from inflammatory disease to cancer - based on the company's proprietary technology, TransKingdom RNA interference (tkRNAi). Cequent's first products, now entering clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease. The company designed its powerful tkRNAi technology to deactivate specific disease-causing genes safely and effectively, using non-pathogenic bacteria as an engine to produce and deliver RNAi directly into cells. It is based on ground-breaking scientific research originating at the Institut Pasteur (Paris, France) and at the Beth Israel Deaconess Medical Center/Harvard Medical School. A privately held company based in Cambridge, Massachusetts, Cequent was established in 2006.

SOURCE Cequent Pharmaceuticals, Inc.

SOURCE Cequent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
2. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
3. Two Luminaries Join Cequent Scientific Advisory Board: Judy Lieberman, M.D. Ph.D., and Patrice Courvalin, M.D.
4. Cequent Names Ted Hibben Chief Business Officer
5. Cequent Names F. Stephen Laroux, Ph.D., Director, Immunology and Inflammatory Diseases
6. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
7. CardioDynamics Provides 2007 Shareholder Meeting Update
8. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
9. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
10. Reed Group to Provide MDA Internet Disability Duration Guidelines to U.S. Navy
11. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
Post Your Comments:
(Date:11/25/2015)... Oregon , November 25, 2015 ... Market Research Report is a professional and in-depth ... industry.      (Logo: ) ... overview of the industry including definitions, classifications, applications ... is provided for the international markets including development ...
(Date:11/24/2015)... DIEGO , Nov. 24, 2015 Halozyme Therapeutics, Inc. ... Healthcare Conference in New York on Wednesday, ... Helen Torley , president and CEO, will provide a corporate ... New York at 1:00 p.m. ET/10:00 a.m. PT ... and investor relations, will provide a corporate overview. --> ...
(Date:11/24/2015)... 2015  Clintrax Global, Inc., a worldwide provider of clinical research ... announced that the company has set a new quarterly earnings record ... quarter growth posted for Q3 of 2014 to Q3 of 2015. ... Mexico , with the establishment of an Asia-Pacific ... United Kingdom and Mexico ...
(Date:11/24/2015)... , November 24, 2015 ... recent market research report released by Transparency Market Research, ... expand at a CAGR of 17.5% during the period ... Testing Market - Global Industry Analysis, Size, Volume, Share, ... global non-invasive prenatal testing market to reach a valuation ...
Breaking Biology Technology:
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
(Date:11/11/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology company ... to announce that it will be a Sponsor of the ... be held November 17-19 in Hamburg , ... iMedNet , MedNet,s easy-to-use, proven and affordable ... been able to deliver time and cost savings of up ...
(Date:11/9/2015)... 09, 2015 ... the "Global Law Enforcement Biometrics Market ... --> ) has announced the ... Biometrics Market 2015-2019" report to their ... ( ) has announced the addition ...
Breaking Biology News(10 mins):